Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Avere Therapeutics: The company entered into a definitive agreement to receive $820 million of development capital from multiple investors. The company is a developer of oral immunology therapies intended to treat inflammatory diseases driven by the interleukin pathway.Vaderis Therapeutics: The company raised $152 million of Series B venture funding in a deal led by TCG Crossover Management, Omega Funds and Goldman Sachs Asset Management on August 11, 2026. The company is a developer of oral medicine designed for the treatment of rare and orphan diseases caused by vascular malformations.Bridge to Life: The company raised $110 million of Series C venture funding through a combination of debt and equity on August 12, 2026. The company is a developer of organ preservation solutions and machine perfusion technologies for transplant centers and organ procurement organizations.Aureka Biotechnologies: The company raised $100 million of Series B venture funding in a deal led by Highlight Capital on August 11, 2026. The company is a developer of AI-enabled biologics discovery technology for designing and optimizing antibody and protein therapeutics.InduPro: The company raised $77 million of Series B venture funding in a deal led by The Column Group on August 12, 2026. The company is an operator of a biopharma platform intended to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.Infinimmune: The company raised $75 million of Series A venture funding in a deal led by Regeneron Ventures and Playground Global on August 11, 2026, putting the company’s pre-money valuation at $51 million. The company is a developer of human-derived antibody discovery technology that mines B-cell repertoires to identify therapeutic antibodies.BoulevardBio: The company raised $65 million of venture funding through a combination of convertible debt and equity from Deerfield Management on August 12, 2026. The company is a developer of multi-specific antibodies designed to modify B cell-driven autoimmune diseases at their source.Flagler Health: The company raised $50 million of Series B venture funding in a deal led by Bessemer Venture Partners on August 11, 2026, putting the company’s pre-money valuation at $200 million. The company is a developer of AI-enabled healthcare operations software for helping medical practices manage revenue cycle, referrals, documentation and patient engagement.Khartis Therapeutics: The company raised $50 million of Series B venture funding in a deal led by Forge Life Science Partners on August 13, 2026, putting the company’s pre-money valuation at $106 million. The company is a developer of oral small-molecule therapeutics designed for the treatment of immune-mediated and chronic diseases.Versa Vascular: The company raised $42 million of Series C venture funding in a deal led by S3 Ventures on August 11, 2026, putting the company’s pre-money valuation at $93 million. The company is a developer of an implant system designed to treat tricuspid regurgitation by supporting native valve function without disrupting cardiac structures.Abcuro: The company raised $66 million of Series D venture funding led by New Leaf Venture Partners on August 13, 2026. The company is a developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer.Remepy: The company raised $36 million of Series A venture funding in a deal led by M Ventures and O.G. Venture Partners on August 12, 2026. The company is a developer of a digital healthcare platform designed to facilitate the creation of hybrid drugs.RapidAI: The company raised $25 million of venture funding in the form of convertible debt financing from undisclosed investors on August 14, 2026. The company is a developer of a neuroimaging platform designed to create quality images from non-contrast image scans.Hyku Biosciences: The company raised venture funding from undisclosed investors on August 13, 2026. The company is a developer of small-molecule therapeutics designed to inactivate disease-driving proteins.BTB Therapeutics: The company raised venture funding from SMBC Venture Capital and other undisclosed investors on August 12, 2026. The company is a developer of non-opioid medicines intended to use small-molecule compounds targeting RNA splicing for the treatment of diseases and cancer immunotherapy.Remedium Bio: The company raised $10 million of Series A venture funding in a deal led by LifeSpan Vision Ventures on August 10, 2026. The company is a gene therapy developer focused on single-injection treatments for osteoarthritis, metabolic, immunology and neurological indications.Auron Therapeutics: The company raised venture funding in the form of convertible debt from undisclosed investors on August 13, 2026. The company is a clinical-stage biotechnology developer of therapies targeting cell-state plasticity in oncology and inflammatory disease.MBQ Pharma: The company raised venture funding from undisclosed investors on August 14, 2026. The company is a developer of targeted therapeutic compounds designed to treat metastatic diseases by disrupting tumor cell motility and halting metastasis progression.Meduloc: The company raised $4 million of Series B venture funding in a deal led by GenHenn Capital on August 14, 2026. The company is a developer of an intramedullary fixation device designed to assist doctors in fixing small and long-bone fractures.

M&A Transactions

Actio Biosciences / Jazz Pharmaceuticals: The company reached a definitive agreement to be acquired by Jazz Pharmaceuticals for $1.3 billion on August 10, 2026. The company is a clinical-stage biotechnology developer of genetics-driven small-molecule precision medicines for rare and common diseases.Kashiv BioSciences / Amneal Pharmaceuticals: The company was acquired by Amneal Pharmaceuticals for $1.1 billion on August 10, 2026. The company is a provider of pharmaceutical research and drug delivery services designed to create improved versions of known medicines with clinical differentiation.Microbiology Business of Thermo Fisher Scientific / Astorg: The microbiology business of Thermo Fisher Scientific was acquired by Astorg through over a $1 billion LBO on August 12, 2026. The company is a provider of microbiology diagnostic services intended to serve the clinical, pharmaceutical, and food safety sectors.ABSCINT / Curium Pharma: The company was acquired by Curium Pharma, via its financial sponsors, Ardian France, ICG Enterprise Trust and TPG through an LBO on August 10, 2026 for an undisclosed amount. The company is a developer of an in vivo molecular imaging diagnostics platform designed to improve patient stratification and treatment monitoring.Alfa Wassermann Separation Technologies / CARR Biosystems: The company, a subsidiary of Alfa Wassermann, was acquired by CARR Biosystems, via its financial sponsor BW Forsyth Partners, through an LBO on August 10, 2026 for an undisclosed amount. The company is a manufacturer of continuous-flow ultracentrifugation and fluid handling systems for bioprocessing and pharmaceutical manufacturing.Everlight Radiology / Partners Group: The company has received bids to be acquired by Radiology Partners and Partners Group through an LBO as of August 16, 2026 for an estimated $1 billion. The company is a provider of radiology reporting services intended to serve hospitals, imaging clinics, and healthcare professionals.Relevate Health Group / Linden: The company was acquired by Linden through an LBO on August 10, 2026. The company is a provider of healthcare professional marketing, omnichannel engagement and data analytics services for life sciences brands.Somatric / Davigo: The company was acquired by Davigo for an undisclosed amount on August 12, 2026. The company is a developer of body-sensing technology for measuring and analyzing physiological signals.The Rounds / Misfits Market, Native Touch: The company was acquired by Misfits Market and Native Touch for an undisclosed amount on August 12, 2026. The company is a secure professional network for healthcare professionals, supporting clinical communities, peer collaboration and medical education.MIMETAS / Bruker: The company was acquired by Bruker on August 10, 2026. The company is a developer of organ-on-a-chip technology designed for drug discovery and human tissue modeling.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker